Gilead Sciences 投資組合持股
Gilead Sciences is an American biopharmaceutical company that researches and develops antiviral drugs for HIV/AIDS, hepatitis B and C, influenza and COVID-19. Michael Riordan, a doctor who was then an associate at the venture firm Menlo Ventures, founded it in 1987 as Oligogen, a name pointing to oligonucleotides, small strands of DNA. Riordan used Oligogen only while clearing a trademark issue with a California nonprofit, and he took the Gilead name from the Balm of Gilead, which he first met in a Lanford Wilson play. Gilead discovered the flu drug Tamiflu and licensed it to Roche, and its 2011 purchase of Pharmasset brought it sofosbuvir, approved in 2013 as the hepatitis C treatment Sovaldi. In 2017 Gilead said it would acquire Kite Pharma as its entry into cell therapy, a deal that had produced two lymphoma treatments, Yescarta and Tecartus, by 2022.
熱門買進
賣出排行
| 排名 | 股票 | 價值 |
|---|---|---|
| 1 |
Kalaris Therapeutics
KLRS
|
+US$183萬 |
| 2 |
ImageneBio
IMA
|
+US$99.2萬 |
| 3 |
BRNS
Barinthus Biotherapeutics
BRNS
|
+US$23.6萬 |
類股組成
| 排名 | 類股 | 權重 |
|---|---|---|
| 1 | 醫療保健 | 99.88% |
| 2 | 金融 | 0.12% |
相似基金
Gilead Sciences的2025年第2季投資組合回顧
截至2025年第2季,Gilead Sciences持有14個部位,價值US$12.8億,較前一季的US$11.8億增加8.4%。 其前十大持股占投資組合的100%。
2025年第2季的交易不活躍:投資組合週轉率為0%。 Gilead Sciences未建立任何新部位,也沒有平倉,因此其由14個部位組成的投資組合大致維持不變。
按類股來看,投資組合最集中於醫療保健,占資產的100%,高於前一季的100%,其次是金融。
- Gilead Sciences在2025年第2季最大幅度減持的標的是Kalaris Therapeutics,估計減持了US$183萬。
- 在2025年第2季,Gilead Sciences的投資組合規模為US$12.8億,前十大持股占100%。
- Gilead Sciences在2025年第2季新增了0個部位,並平倉0個部位。
- Gilead Sciences的投資組合價值較前一季上升8.4%,達到US$12.8億。
根據Gilead Sciences的2025年第2季 13F申報資料 ,於2025年8月14日提交。